Biologics APIs

Jun 04, 2018
By Pharmaceutical Technology Editors
EMA has recommended marketing authorization for Aimovig (erenumab), a new treatment for migraine.
Jun 04, 2018
By Pharmaceutical Technology Editors
The agency has recommended approval of three biosimilar adalimumab products from Novartis, referencing AbbVie’s Humira, and a biosimilar trastuzumab from Pfizer, referencing Roche’s Herceptin.
Jun 01, 2018
By Pharmaceutical Technology Editors
TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.
Jun 01, 2018
By Pharmaceutical Technology Editors
Catalent’s GPEx technology was used to develop antibody for anti-methamphetamine clinical study.
May 30, 2018
By Pharmaceutical Technology Editors
GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.
May 29, 2018
By Pharmaceutical Technology Editors
The European Commission has approved Zessly (infliximab), a biosimilar to Johnson & Johnson’s blockbuster Remicade (infliximab).
May 29, 2018
By Pharmaceutical Technology Editors
This marks the third FDA approval for the company’s second biomanufacturing plant in Incheon, Korea.
May 25, 2018
By Pharmaceutical Technology Editors
The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.
May 23, 2018
By Pharmaceutical Technology Editors
The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.
May 16, 2018
By Pharmaceutical Technology Editors
Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.
native1_300x100
lorem ipsum